Tevogen Initiates Commercial Readiness for PredicTcell AI Model After 10% Precision Gain
Tevogen’s PredicTcell AI model has completed training on one of the largest curated peptide datasets, expanding to over 180 parameters and delivering a roughly 10% gain in precision. The company has initiated commercial readiness by evaluating co-development partnerships and launching an internal application portal for scalable platform deployment.
1. PredicTcell Training Progress
PredicTcell has progressed to final training stages after processing one of the industry’s largest curated peptide datasets. Feature expansion now exceeds 180 parameters, delivering an approximate 10% improvement in peptide identification precision.
2. Commercial Readiness and Partnership Evaluation
Tevogen has begun evaluating co-development partnerships to extend PredicTcell use beyond internal research. These collaborations aim to address high-confidence target identification challenges, reducing drug development timelines, material costs and experimental burden.
3. Internal Application Portal Development
An initial internal portal has been launched to deploy PredicTcell in a scalable, user-friendly environment. This foundation will support streamlined workflows and serve as the basis for a future customer-facing platform.